PATENT CLAIM ANALYSIS

Application Number: 16209112
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-09
Patent Classification: ["514", "380000"]

Abstract:
In one aspect, the invention relates to compounds having the formula: where X, R a , R b , R 2 , and R 7  are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds are prodrugs of compounds having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising these compounds; methods of using these compounds; and processes and intermediates for preparing these compounds.

Claim (Index 45):
The method of  claim 44 , wherein the AT 1  receptor antagonist is selected from abitesartan, azilsartan, azilsartan medoxomil, benzyllosartan, candesartan, candesartan cilexetil, elisartan, embusartan, enoltasosartan, eprosartan, EXP3174, fonsartan, forasartan, glycyllosartan, irbesartan, isoteoline, losartan, medoximil, milfasartan, olmesartan, olmesartan medoxomil, opomisartan, pratosartan, ripisartan, saprisartan, saralasin, sarmesin, TAK-591, tasosartan, telmisartan, valsartan, and zolasartan.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 98.0
- Lexical Diversity: 1.67347
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13961269', '13911819', '13911552', '14812095', '14838842']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7984913910698604
- 35 USC 102 Novelty (BERT): 0.5833862796226184
- Combined Prediction Score: 0.7769808799251363
- Mean Citation Score: 414.121838
- Max Citation Score: 497.09735
- Similarity Product: 390.1866776051343

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test